Resumen

BELLIDO-CAPARO, Álvaro; ROSADO, Mavel; ESPINOZA-RIOS, Jorge  y  TAGLE ARROSPIDE, Martin. Successful treatment with new direct acting antiviral in an infected patient with hepatitis C virus with advanced liver fibrosis in a treatment experienced patient: Case report. Rev Med Hered [online]. 2017, vol.28, n.3, pp.187-191. ISSN 1018-130X.  http://dx.doi.org/https://doi.org/10.20453/rmh.v28i3.3187.

The treatment of hepatitis C virus utilized was Pegylated Interferon and Ribavirin, achieving a sustained virological response (SVR) of about 50 %. With the addition of the first-generation protease inhibitors Telaprevir and Boceprevir to the Pegylated Interferon/Ribavirin backbone the SVR rates rose up to approximately 70%, but with important side effects and a difficult adherence. The new direct acting antivirals (NS5A and NS5B polymerase inhibitors) improved SVR rates to 95 % or greater in the different genotypes, in the treatment-naive and treatment experienced patients including patients with cirrhosis. We report the case of a patient with advanced fibrotic stage, who failed to respond to 2 regimens and was subsequently treated with Ledipasvir/Sofosbuvir and achieved virogical cure.

Palabras clave : Hepatitis C; Pegylated interferon; sofosbuvir; ledipasvir.

        · resumen en Español     · texto en Español     · Español ( pdf )